Brought to you by 
Essex Woodlands leads $40.4mm Series C round for Catalyst
19 Mar 2013
Executive Summary
First-time investor Essex Woodlands led the $40.4mm Series C financing for Catalyst Biosciences (redesigns proteases--called Alterases--that target disease-causing proteins). Returning backers Burrill & Co., HealthCare Ventures, Johnson & Johnson Development Corp., Morgenthaler Ventures, Novartis BioVentures, and Sofinnova Ventures also participated. A managing director from Essex joined the company's board. Catalyst says it will now have enough money to support its activities for the next few years, including moving its CB813 Factor VIIa treatment for hemophilia (currently at the preclinical stage) through Phase I/II proof-of-concept studies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Essex Woodlands leads $40.4mm Series C round for Catalyst
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice